A special committee composed entirely of independent directors has been formed to evaluate the proposal. Supported by a team of legal and financial advisors, the committee is tasked with determining whether the bid serves the best interests of shareholders. The board has opted to remain silent on the specifics of the offer while the review process is underway.

InMode, a global developer of radiofrequency-based surgical and dermatological devices, has not provided a timeline for its decision. The company maintains that any potential outcome remains subject to the committee's fiduciary assessment and broader market conditions, including the possibility of competing offers or the withdrawal of the current bid.